title: Immunotherapeutic approaches in chronic myelogenous leukemia.
abstract: Chronic myeloid leukemia (CML) is a stem cell disease in which BCR/ABL plays an important role as oncoprotein and also as a molecular and immunogenic target. In fact, several molecular targeted drugs and immunotherapies have been developed for this disease. In the current article, several immunotherapeutic approaches in CML, including interferon-alpha and vaccination, are discussed along with results from clinical trials and the value of such immunotherapies in the imatinib-era.
authors.affiliation: Department of Oncology-Haematology and Cell Therapy, EA 3805 and Clinical Research Centre, CHU de Poitiers, Poitiers, France. f.guilhot@chu-poitiers.fr
authors.forename: François
authors.initials: F
authors.lastname: Guilhot
authors.forename: Lydia
authors.initials: L
authors.lastname: Roy
authors.forename: Pierre-Jean
authors.initials: PJ
authors.lastname: Saulnier
authors.forename: Joëlle
authors.initials: J
authors.lastname: Guilhot
authors.forename: Anne
authors.initials: A
authors.lastname: Barra
authors.forename: Jean-Marc
authors.initials: JM
authors.lastname: Gombert
authors.forename: Ali
authors.initials: A
authors.lastname: Turhan
mesh_terms: D001549:Benzamides; D006801:Humans; D000068877:Imatinib Mesylate; D007167:Immunotherapy / Q000379:methods*; D016898:Interferon-alpha; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*; D010879:Piperazines; D011743:Pyrimidines; D014612:Vaccines
chemical_list: D001549:Benzamides; D016898:Interferon-alpha; D010879:Piperazines; D011743:Pyrimidines; D014612:Vaccines; D000068877:Imatinib Mesylate